ResMed (RMD)
(Delayed Data from NYSE)
$272.60 USD
+1.41 (0.52%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $272.60 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RMD 272.60 +1.41(0.52%)
Will RMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RMD
Here's Why ResMed (RMD) is a Strong Growth Stock
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why ResMed (RMD) is a Strong Growth Stock
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Other News for RMD
Is RMD consolidating before a move? NR7 shows up after climbing 0.39%
UBS Keeps Their Buy Rating on Resmed (RMD)
Short bets on S&P 500 Healthcare sector eases in August; MRNA stays most shorted stock
UBS Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
ResMed participates in a conference call with KeyBanc